AbbVie (ABBV) has been making notable strides in the stock market. Echoing a bullish sentiment, shares soared 3.61% due to deals in cancer therapy. Positive strides have been made in their real-world study on
ABBV-951, creating hope for a breakthrough in
Parkinson's treatments. Their significant <$700M> upfront investment for a triple-target cancer drug further bolsters their drive for innovation. On the downside, potential shareholders are cautioned against hasty decisions for dividends, with a more secure long-term outlook recommended. Amid these developments,
Morgan Stanley maintains an overweight rating on AbbVie, expressing optimism about its future growth. Other deals include a $2.1B acquisition of
Capstan Therapeutics that strengthens AbbVie's autoimmune pipeline. However, AbbVie's stock dipped around 13% during a three-month span, sparking debate among investors whether to buy the dip. Their
EPS and dividend growth has been explosive, but Q2 earnings forecasts lower due to R&D costs. Despite a failed late-stage trial for their blood cancer drug, positive phase 3 results for their migraine drug Atogepant offers encouragement. Their diversification strategy displayed resilience after the Venetoclax MDS setback, and AbbVie moves to market domination after a blockbuster loss.
Abbvie ABBV News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Sat, 12 Jul 2025 02:54:23 GMT -
Rating 7
- Innovation 6
- Information 9
- Rumor 3
